Peter Sieger, Mittelbiberach (DE); Dirk Kemmer, Windesheim (DE); Peter Kohlbauer, Biberach an der Riss (DE); Thomas Nicola, Mainz (DE); and Martin Renz, Eberhardzell-Dietenwengen (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Jun. 30, 2021, as Appl. No. 17/363,441.
Application 17/363,441 is a division of application No. 16/662,406, filed on Oct. 24, 2019, granted, now 11,084,819.
Application 16/662,406 is a continuation of application No. 16/373,971, filed on Apr. 3, 2019, abandoned.
Application 16/373,971 is a continuation of application No. 15/725,426, filed on Oct. 5, 2017, granted, now 10,301,313, issued on May 28, 2019.
Application 15/725,426 is a continuation of application No. 15/285,871, filed on Oct. 5, 2016, granted, now 9,815,837, issued on Nov. 14, 2017.
Application 15/285,871 is a continuation of application No. 14/994,578, filed on Jan. 13, 2016, granted, now 9,493,462, issued on Nov. 15, 2016.
Application 14/994,578 is a continuation of application No. 14/462,654, filed on Aug. 19, 2014, granted, now 9,266,888, issued on Feb. 23, 2016.
Application 14/462,654 is a continuation of application No. 13/563,767, filed on Aug. 1, 2012, abandoned.
Application 13/563,767 is a continuation of application No. 11/744,700, filed on May 4, 2007, abandoned.
Claims priority of application No. 06009202 (EP), filed on May 4, 2006.
Prior Publication US 2021/0323964 A1, Oct. 21, 2021
1. A method for the treatment of patients with type II diabetes mellitus, the method comprising the step of administering to the patient a pharmaceutical composition comprising anhydrous polymorph A of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and one or more inert carriers, wherein the pharmaceutical composition comprises 0.1% to 0.5%, or 0.5% to 1.5%, or 1% to 3% of anhydrous polymorph A.